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Abstract
A deﬁnitive diagnosis of zygomycosis caused by Mucorales can be made by histopathological examination with or without isolation of
the fungus from the same site. Histopathological examination of the tissues affected typically shows characteristic broad, hyaline, rib-
bon-like, irregular fungal hyphae with wide-angle branching, accompanied by tissue necrosis and angioinvasion of the fungi. Tissue inva-
sion by the fungal hyphae as seen by microscopy is essential to establish the diagnosis. Fungal elements can be stained with Gomori
methenamine-silver, periodic acid-Schiff or Calcoﬂour white stain. All Mucorales grow rapidly on most fungal media such as Sabouraud
dextrose agar incubated at 25–30 C. Mucorales from a sterile site or repeated positive cultures of the fungi from a non-sterile site are
considered signiﬁcant in a high-risk patient with predisposing factors for acquisition of zygomycosis. Positive cultures from non-sterile
specimens should be interpreted with caution and will require correlation between the ﬁnding and the clinical situation.
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Introduction
Although Aspergillus species, particularly Aspergillus fumigatus,
account for the largest proportion of invasive mould infec-
tions, the last decade has witnessed the emergence of new
opportunistic pathogens, including non-fumigatus Aspergillus
species, Fusarium species, Scedosporium species, the dematia-
ceous fungi (Alternaria, Bipolaris, Curvularia, Cladosporium
and Exserohilum species) and the agents of zygomycosis
(mucormycosis) [1–3].
The class Zygomycetes includes a variety of ﬁlamentous
fungi that may cause human disease and have emerged as an
important cause of morbidity and mortality among immuno-
compromised patients [4,5]. The medically important Zygomy-
cetes encompass two orders of ﬁlamentous fungi with distinct
morphological, epidemiological and pathogenic characteristics,
the Mucorales and the Entomophthorales [5]. The majority of
cases of zygomycosis in humans are caused by members of the
order Mucorales. Organisms of the genus Rhizopus are by far
the most common clinical isolates, with Rhizopus oryzae occcur-
ring most frequently. Members of the genus Mucor are second
to Rhizopus in order of frequency, whereas Cunninghamella,
Apophysomyces, Absidia, Saksenaea, Rhizomucor and other gen-
era each represent a signiﬁcantly smaller percentage of clinical
isolates [4–7]. Zygomycetes are ubiquitous in soil and the envi-
ronment and occasionally colonize humans.
The diseases produced by these fungi are referred to by
the label ‘zygomycosis’. Manifestations depend on the loca-
tion of involvement, but they typically concern rhinocerebral,
pulmonary, cutaneous, gastrointestinal and central nervous
system (CNS) diseases [4–7].
Zygomycetes are characterized in culture by broad, non-
septate or sparsely septated hyphae and by the presence of
sporangiophores supporting sporangia, which contain sporan-
giospores [5]. During sexual reproduction in culture, zygo-
spores may be produced. Zygomycetes are characterized in
tissue by the formation of wide, ribbon-like, hyaline, aseptate
or sparsely septated hyphae with wide-angle (approximately
90 ) branching. The substantial differences among these and
other structures allow mycology laboratories to diagnose
organisms by genus and species [5].
Laboratory Diagnosis
As infections caused by Zygomycetes, and particularly the
Mucorales, in humans may be rapidly fatal, timely diagnosis is
crucial to avoid treatment delay [8,9]. Although conﬁrmation
of the diagnosis and species identiﬁcation of the causative
organism should be pursued, treatment should be initiated as
soon as the diagnosis is suspected because of the severity of
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these infections. The diagnosis of zygomycosis relies on a
constellation of a high index of suspicion, assessment of pre-
senting signs and symptoms, imaging studies, cultures and
direct examinations of clinical specimens, and histopathology
[10,11].
Suspicion should be based on knowledge of the underlying
conditions that predispose to zygomycosis and the usual pre-
sentation of the infection in each of these conditions [12,13].
A common scenario concerns the development of zygo-
mycosis in oncological patients or transplant recipients who
receive antifungal therapy for prophylaxis or treatment of
other opportunistic fungal infections [9,14–18]. In such cases
the antifungal agents administered are not active against
Zygomycetes, such as ﬂuconazole, voriconazole and the echi-
nocandins. Most of the signs and symptoms associated with
the clinical manifestations of zygomycosis are non-speciﬁc.
However, their diagnostic signiﬁcance may increase if they
are interpreted in relation to the patient’s underlying condi-
tion. Early diagnosis is the cornerstone of successful treat-
ment of zygomycosis; indeed, a direct correlation has been
established between early tissue diagnosis and survival [10].
However, as is the case with many fungal infections, diagno-
sis is often not possible until autopsy [1,10].
Clinical specimens
The reference standard for the deﬁnite diagnosis of zygomy-
cosis concerns histopathological, cytopathological or direct
microscopic examination from affected organs [1,5,19,20].
The diagnosis relies on the evidence of tissue invasion. Thus,
specimens obtained should be processed for fungal stains,
cultures and any other procedures (e.g. molecular-based
analyses) appropriate for ruling out differential diagnoses
(Fig. 1). Combining microscopy and culture will increase the
diagnostic yield by 15–20% [4,10,21].
Adequate specimens are skin scrapings from cutaneous
lesions, nasal discharges, scrapings and aspirates from sinuses
in patients with rhinocerebral lesions, bronchoalevolar lavag-
es and needle biopsies from pulmonary lesions, and biopsy
tissue from patients with gastrointestinal and/or disseminated
disease. Blood cultures are of no beneﬁt. If CNS abnormali-
ties are present, brain biopsy may be helpful along with anal-
yses of the cerebrospinal ﬂuid. Unfortunately, even in brain
involvement, fungal stains and culture results are rarely posi-
tive. Overall, it is important to collect many proper clinical
specimens in order to obtain a high-yield result because
Mucorales are sometimes difﬁcult to distinguish from other
ﬁlamentous fungi in histopathological examination [19,20].
Zygomycetous fungi have primitive coenocytic hyphae, which
become easily damaged during biopsy procedures or tissue
grinding in the laboratory. Thus, they are not suitable for
growing in culture despite their presence in microscopic or
histopathological examinations; in fact, fungal cultures are
positive in only 15–25% of cases [6, 22].
Direct microscopic examination
Aspirated material from sinuses, sputum in pulmonary
disease and biopsy material should be analysed using 10%
potassium hydroxide (KOH) or optical brighteners such as
Fungi-FluorTM (Calcoﬂuor white staining solution; Polyscien-
ces, Inc., Warrington, PA, USA) or Blancophor (Bayer AG,
Leverkusen, Germany) [10, 23]. Demonstration of fungal ele-
ments from cytological preparations (i.e. sputa, inﬂammatory
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FIG. 1. Zygomycosis: diagnostic approach
using microscopic and culture techniques.
BAL, Broncho-alveolar lavage; TS, Tracheal
secretions.
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ﬂuid aspirates from abscesses or sinusitis infection) may be
complex as a result of the difﬁculty in extracting fungal ele-
ments from invaded tissues. Fungal elements may be rare in
cytological specimens and, when present, are often frag-
mented. The key features associated with Zygomycetes are
typically thick-walled, refractile hyphae 6–15 lm in diameter,
swollen cells (£50 lm) and, sometimes, distorted hyphae
(Fig. 2). The width of the hyphal element varies substantially.
A positive direct microscopy, especially from a sterile site,
must be considered signiﬁcant, even if the laboratory is
unable to culture the fungus. The combined application of
KOH and brighteners is possible.
Histopathology
The diagnosis of zygomycosis is made on tissue section.
Acute suppurative inﬂammation predominates, with focal
areas of granulomatous inﬂammation. Hyphae usually vary
from 6 lm to 30 lm in diameter, and are sparsely septate
and irregularly branched. The organism characteristically
invades the walls of adjacent blood vessels, causing thrombo-
sis and infarction. Stains of ﬁxed tissues with haematoxylin
and eosin (H&E) or specialized fungal stains, such as Grocott
methenamine-silver (GMS) or periodic acid-Schiff (PAS)
stains show broad-based, ribbon-like, non-septate hyphae
with wide-angle branching (approximately 90 ) (Fig. 3) [5].
The hyphae are often not well preserved and may become
crinkled or gnarled in the tissue sections. This appearance of
the hyphal elements is often described as resembling ‘crin-
kled cellophane’. Cross-sections of hyphal elements often
give tissues a vacuolated appearance. These cross-sections
vary in diameter and may be confused with yeast cells The
H&E stain should always be conﬁrmed with a more fungus-
speciﬁc tissue stain such as GMS or PAS. The application of
optical brighteners in such specimens is also possible.
Culture
These fungi can be very difﬁcult to recover. It is recom-
mended that the clinical material is inoculated onto Sabou-
raud dextrose agar and incubated at 30 C (or 37 C) for a
minimum of 3–5 days [5]. The growth of the Mucorales
tends to be rapid, with mycelial elements expanding to cover
the entire plate in only a few (1–7) days. The sporulating
surface of the colonies may demonstrate variable degrees of
coloration. Depending upon the order, species or individual
isolate, Zygomycetes will demonstrate surface colouration
FIG. 2. Direct microscopic examination. Computed tomography-
guided percutaneous lung biopsy stained with Fungi-Fluor shows typi-
cally distorted, non-septate and broad hyphae.
FIG. 3. Periodic acid-Schiff staining of computed tomography-guided
percutaneous lung biopsy shows broad-based, ribbon-like, non-sep-
tate hyphae with right-angle branching and swollen cells.
FIG. 4. Microscopic feature of Mucor sp. in culture. Lactophenol
cotton blue staining shows a globose intact sporangium with sporan-
giospores and branched sporangiophores. Stolons and rhizoids are
absent.
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varying from pure white to tan, brown, grey, or even black.
Brain-heart-infusion (BHI) broth with penicillin is added to
the normal battery when Zygomycetes are suspected. The
use of broth provides optimal medium–specimen contact.
The aseptic addition of sterile penicillin discs will inhibit bac-
teria. Malt extract agar is an effective alternative to broth
media for the isolation of Zygomycetes. BHI broth may be
used routinely by some ophthalmologists for corneal scrap-
ings [5]. Sterile bread without preservatives is recommended
for the recovery of Zygomycetes from clinical specimens.
Bread is often superior to other media used for recovering
these pathogens. A piece of bread is sterilized in a humidiﬁed
Petri dish. Specimens from non-contaminated sites can be
directly inoculated. Contaminated specimens should be trea-
ted with antibacterial agents before inoculation. Zygomycetes
will grow rapidly, often ﬁlling the entire Petri dish within a
few days [4–6].
Recovery of Zygomycetes from cultures of clinical speci-
mens allows not only for diagnosis, but also for the identiﬁ-
cation of the causative organism to species level. Although
Zygomycetes may contaminate laboratory material, their
isolation from clinical specimens of susceptible hosts should
not be disregarded as contamination. The isolation of Zygo-
mycetes in patients with leukaemia had a positive predictive
value of 88% [24]. Despite the ability of these organisms to
invade tissues, they are rarely isolated from cultures of
blood, urine, cerebrospinal ﬂuid, faeces, sputum, paranasal
sinuse secretions, bronchoalveolar lavage or swabs from
infected areas. The recovery of Zygomycetes from biopsy
material may be compromised if the processing of the
TABLE 1. Differentiating features of the sporangium-producing Mucorales
Organism Best growth, C Sporangiophore Apophysis Columella Sporangium Rhizoids
Absidia sp. 37 Branched, hyaline Conical Dome-shaped Pear-shaped Primitive, rare
Apophysomyces sp. 24–42 Non-branched, brown Bell-shaped Rarely elongated Pear-shaped Tuft, originating from a foot cell
Mortierella sp. >40 Branched, hyaline – – Spherical Primitive
Mucor sp. <37 Branched, non-branched, hyaline – Varying shapes Spherical Absent
Rhizomucor sp. 20–60 Branched, brown – Spherical Spherical Primitive, rare
Rhizopus sp. 37 Non-branched, brown Not prominent Spherical Spherical Abundant, often well developed
Adopted from Ribes et al. [26].
TABLE 2. Minimum inhibitory (MIC) and fungicidal concentrations (MFC) of various antifungals against Zygomycetes. Tests
were performed according to EUCAST methodology
Species
MIC, mg/L MFC, mg/L
Range 90% Mean Range 90% Mean
Rhizomucor sp. (n = 17)
Amphotericin B 0.5–1 1 0.68 1–4 4 1.79
Liposomal AMB 0.06–0.5 0.5 0.25 0.125–1 1 0.55
Voriconazol >8 >8 >8 >8 >8 >8
Itraconazol 1 to >8 >8 >8 2 to >8 >8 >8
Posaconazol 1–8 4 2.7 2–8 8 5.7
Absidia sp. (n = 7)
Amphotericin B 0.5–2 1 0.89 1–8 4 2.21
Liposomal AMB 0.125–4 2.5 1.25 0.25–8 4 2.54
Voriconazol >8 >8 >8 >8 >8 >8
Itraconazol 1 to >8 >8 >8 2 to >8 >8 >8
Posaconazol 0.25–2 1 0.88 0.5–4 2 1.75
Rhizopus sp. (n = 12)
Amphotericin B 1–4 2 3 2–8 8 6
Liposomal AMB 0.25–4 2 2.46 0.5–8 4 3.93
Voriconazol >8 >8 >8 >8 >8 >8
Itraconazol 2 to >8 >8 >8 4 to >8 >8 >8
Posaconazol 1–16 4 2.86 2–8 8 5.70
Mucor sp. (n = 17)
Amphotericin B 0.5–1 1 0.79 1–2 2 1.57
Liposomal AMB 0.125–0.25 0.25 0.25 0.25–1 0.5 0.54
Voriconazol >8 >8 >8 >8 >8 >8
Itraconazol 2 to >8 >8 >8 4 to >8 >8 >8
Posaconazol 1–2 2 1.29 2–8 4 2.86
Fusarium sp. (n = 19)
Amphotericin B 1–4 4 0.79 1–2 2 1.57
Liposomal AMB 0.5–4 4 0.25 0.25–1 0.5 0.54
Voriconazol 0.5–8 2 2.12 4–8 8 4.01
Itraconazol 2 to >8 >8 >8 4 to >8 >8 >8
Posaconazol >8 >8 >8 >8 >8 >8
AMB, amphotericin B.
Data generated from Lass-Flo¨rl et al. [32] and Perkhofer et al. [33].
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specimens involves tissue grinding, a procedure that kills the
non-septate hyphae of these fungi. The recovery rate is
enhanced, however, if thin slices of minimally manipulated tis-
sue are placed onto the culture medium [4–6]. Exudates and
necrotic tissue contain few viable organisms; thus the inocu-
lum from these specimens must be heavy. Zygomycetes do
not survive for more than a few hours at refrigerator tem-
peratures; therefore, if culture is delayed, storage at room
temperature is recommended [6]. In any case, negative cul-
tures do not rule out the infection.
A culture result from a non-sterile body site is not in itself
diagnostic of infection because these fungi are common in
the environment [24, 25]. In one study, only 16 of the sam-
ples which grew Zygomycetes (7.6%) came from infected
patients [24].
Serology
Development of serological tests for diagnosis of zygomyco-
sis by means of antigen and/or antibody detection has been
attempted. Antibodies to Zygomycetes can be detected by
enzyme-linked immunosorbent assays (ELISAs) and double
diffusion [26]. Immunoblot analyses have also been used to
detect Rhizopus arrhizus antigens [27]. However, these sero-
logical tests for zygomycosis cannot be recommended with-
out further clinical evaluation and are not available for
routine use at this time. Recently, Japanese researchers
observed that serum IgE and Mucor IgE antibody were
related to invasiveness of orbital mucormycosis [28].
Species Identiﬁcation
Zygomycetes are usually fast-growing fungi characterized by
primitive, mostly aseptated hyphae. Asexual spores include
chlamydoconidia and sporangiospores contained in sporangia
borne on simple or branched sporangiophores. Sexual repro-
duction is isogamous and produces a thick-walled sexual
resting spore called a zygospore [5, 26].
Most isolates are heterothallic; thus zygospores are absent
and identiﬁcation is based primarily on sporangial morpho-
logy. This includes the arrangement and number of spor-
angiospores, the shape, colour, presence or absence of
columellae and apophyses, as well as the arrangement of the
sporangiophores and the presence or absence of rhizoids.
Lactophenol cotton blue can be used to achieve better visu-
alization (Fig. 4) [5, 26].
Growth temperature studies (25 C, 37 C, 45 C) can
be helpful in identifying culture characteristics. Sporulation
may be stimulated by the use of nutrient-deﬁcient media,
such as cornmeal–glucose–sucrose–yeast extract agar or
Czapek Dox agar. Features that help in the differentiation of
these genera are summarized in Table 1.
In vitro Susceptibility
Available methods for susceptibility testing are the EUCAST-
reference method for spore-forming moulds [29], the M38-A
reference method for ﬁlamentous fungi [30] and the Etest
(AB Biodisk, Solna, Sweden).
With these fungi it is often difﬁcult to achieve accurate and
consistent endpoints. As the interpretive MIC breakpoints
have not yet been deﬁned for Zygomycetes and the correla-
tions between clinical response and MIC values for a given
strain are uncertain, the use of antifungal susceptibility testing
in zygomycosis for routine clinical decisions is not recom-
mended at this time [31, 32].
Zygomycetes appear to be susceptible to amphotericin B
and are generally not susceptible to the triazoles and echino-
candins (Table 2) [32, 33]. Among the extended-spectrum
triazoles, posaconazole appears to be active against most of
the Zygomycetes [32, 33].
Conclusions
Conventional, routine laboratory diagnostic techniques play
an important role in the diagnosis of and treatment of
zygomycosis. However, expertise is needed in isolating the
agents of this disease. It is paramount to identify the causal
agent so that appropriate treatment can be instigated based
on our current understanding of antifungal sensitivities.
Increasing effort should be put into developing new sero-
logical tests.
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